The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

(RTTNews) - Sanofi said that the U.S. Food and Drug Administration has approved a Biologics License Application for MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive ...

Dublin, June 12, 2020 (GLOBE NEWSWIRE) -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

European Commission approves MenQuadfi ®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC approval based on robust data from seven ...

FDA to review MenQuadfi TM 1, a meningococcal vaccine candidate PARIS - June 27, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA ...

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...

The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria - A, C, W and Y ...